Triptans and CGRP blockade: impact on the cranial vasculature

Research output: Contribution to journalReviewResearchpeer-review

Standard

Triptans and CGRP blockade : impact on the cranial vasculature. / Benemei, Silvia; Cortese, Francesca; Labastida-Ramírez, Alejandro; Marchese, Francesca; Pellesi, Lanfranco; Romoli, Michele; Vollesen, Anne Luise; Lampl, Christian; Ashina, Messoud; School of Advanced Studies of the European Headache Federation (EHF-SAS).

In: Journal of Headache and Pain, Vol. 18, 103, 10.10.2017.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Benemei, S, Cortese, F, Labastida-Ramírez, A, Marchese, F, Pellesi, L, Romoli, M, Vollesen, AL, Lampl, C, Ashina, M & School of Advanced Studies of the European Headache Federation (EHF-SAS) 2017, 'Triptans and CGRP blockade: impact on the cranial vasculature', Journal of Headache and Pain, vol. 18, 103. https://doi.org/10.1186/s10194-017-0811-5

APA

Benemei, S., Cortese, F., Labastida-Ramírez, A., Marchese, F., Pellesi, L., Romoli, M., ... School of Advanced Studies of the European Headache Federation (EHF-SAS) (2017). Triptans and CGRP blockade: impact on the cranial vasculature. Journal of Headache and Pain, 18, [103]. https://doi.org/10.1186/s10194-017-0811-5

Vancouver

Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M et al. Triptans and CGRP blockade: impact on the cranial vasculature. Journal of Headache and Pain. 2017 Oct 10;18. 103. https://doi.org/10.1186/s10194-017-0811-5

Author

Benemei, Silvia ; Cortese, Francesca ; Labastida-Ramírez, Alejandro ; Marchese, Francesca ; Pellesi, Lanfranco ; Romoli, Michele ; Vollesen, Anne Luise ; Lampl, Christian ; Ashina, Messoud ; School of Advanced Studies of the European Headache Federation (EHF-SAS). / Triptans and CGRP blockade : impact on the cranial vasculature. In: Journal of Headache and Pain. 2017 ; Vol. 18.

Bibtex

@article{3d51041dd58a43aeaa9635bf2c10869b,
title = "Triptans and CGRP blockade: impact on the cranial vasculature",
abstract = "The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and migraine pharmacological triggers may act in perivascular space. This review reports the effects of triptans and CGRP blocking molecules on cranial vasculature in humans, focusing on their specific relevance to migraine treatment.",
keywords = "Journal Article, Review",
author = "Silvia Benemei and Francesca Cortese and Alejandro Labastida-Ram{\'i}rez and Francesca Marchese and Lanfranco Pellesi and Michele Romoli and Vollesen, {Anne Luise} and Christian Lampl and Messoud Ashina and {School of Advanced Studies of the European Headache Federation (EHF-SAS)}",
year = "2017",
month = "10",
day = "10",
doi = "10.1186/s10194-017-0811-5",
language = "English",
volume = "18",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Triptans and CGRP blockade

T2 - impact on the cranial vasculature

AU - Benemei, Silvia

AU - Cortese, Francesca

AU - Labastida-Ramírez, Alejandro

AU - Marchese, Francesca

AU - Pellesi, Lanfranco

AU - Romoli, Michele

AU - Vollesen, Anne Luise

AU - Lampl, Christian

AU - Ashina, Messoud

AU - School of Advanced Studies of the European Headache Federation (EHF-SAS)

PY - 2017/10/10

Y1 - 2017/10/10

N2 - The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and migraine pharmacological triggers may act in perivascular space. This review reports the effects of triptans and CGRP blocking molecules on cranial vasculature in humans, focusing on their specific relevance to migraine treatment.

AB - The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and migraine pharmacological triggers may act in perivascular space. This review reports the effects of triptans and CGRP blocking molecules on cranial vasculature in humans, focusing on their specific relevance to migraine treatment.

KW - Journal Article

KW - Review

U2 - 10.1186/s10194-017-0811-5

DO - 10.1186/s10194-017-0811-5

M3 - Review

C2 - 29019093

VL - 18

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

M1 - 103

ER -

ID: 186152362